Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Charles‐Schoeman, Christina; H Buch, Maya; Dougados, Maxime; L. Bhatt, Deepak; T. Giles, Jon; R. Ytterberg, Steven; G. Koch, Gary; Vranić, Ivana; Wu, Joseph; Wang, Cunshan; Kwok, Kenneth; Menon, Sujatha; L. Rivas, Jose; Yndestad, Arne; A. Connell, Carol; Szekanecz, Zoltán

doi:10.1136/ard-2022-222259

Public

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Published in Annals of the Rheumatic Diseases • Sep 22, 2022

Authors:

Christina Charles‐Schoeman

Maya H Buch

Maxime Dougados

Abstract

OBJECTIVES: Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance. METHODS: Patients with...

View

Open Access

Subject

Medicine

Tofacitinib

Rheumatoid arthritis

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!